RARE Insider Trading Activity and SEC Form 4 Filings
RARE insider trading summary
Over the past 12 months, insiders at Ultragenyx Pharmaceutical Inc. (RARE) reported 26 sales worth $3.7M by 9 insiders and no open-market purchases on SEC Form 4. Net insider selling was $3.7M.
Latest RARE insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 15, 2026 | Howard Horn | Chief Financial Officer | Sell | $108K (7,066 @ $15.27) |
| Sep 15, 2026 | Theodore Alan Huizenga | SVP, Chief Accounting Officer | Sell | $17K (1,283 @ $13.57) |
| Sep 3, 2026 | Theodore Alan Huizenga | SVP, Chief Accounting Officer | Sell | $2K (161 @ $13.99) |
| Aug 3, 2026 | Karah Herdman Parschauer | EVP and Chief Legal Officer | Sell | $47K (1,900 @ $24.92) |
| Aug 3, 2026 | Howard Horn | Chief Financial Officer | Sell | $117K (4,696 @ $24.92) |
| Jul 1, 2026 | Howard Horn | Chief Financial Officer | Sell | $156K (4,698 @ $33.13) |
| Jun 15, 2026 | Karah Herdman Parschauer | EVP and Chief Legal Officer | Sell | $47K (1,899 @ $24.62) |
| Jun 15, 2026 | Corazon (Corsee) D. Sanders | Insider | Sell | $50K (2,000 @ $25.05) |
| May 18, 2026 | Shehnaaz Suliman | Insider | Sell | $144K (5,740 @ $25.12) |
| May 5, 2026 | Eric Crombez | EVP and Chief Medical Officer | Sell | $9K (344 @ $24.96) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.